Fig. 10: Agonistic CD40 treatment improves AT3 tumor response to RT + CTLA4i.

C57BL/6 female mice were injected s.c. with AT3 cells at day 0 in the flank. a Treatment schedule. b Waterfall plots of tumor volume change between day 15 and day 35 post-tumor inoculation. Treatment groups were compared by Mann–Whitney tests on Log-transformed values for statistical significance. All statistical tests were two-sided. c Survival (n = 10 biologically independent mice/group except for control n = 5). d Response to treatment of each mouse measured using the 5-category method, as in Fig. 6. e Mice were injected with AT3 tumors in both flanks, radiation was given only to one tumor and CTLA4i and/or anti-CD40 were given according to the schema in (a) (n = 12 mice per group). Tumor growth curves for irradiated (e) and abscopal (f) tumors, mean ±SEM. Statistical significance was assessed by repeated-measures 2-way ANOVA. g Survival (p < 0,001; log rank test). h Relative tumor volume was calculated using the total (primary + abscopal) tumor volume in comparison to the total tumor volume at day of treatment start. Response to treatment was assessed using the 5-cat method. Maintained complete responders rejected both irradiated and abscopal tumors and remained tumor-free until the end of the experiment. i Complete tumor regression observed on primary/secondary or both tumors for each treatment combination group. *,**, ***, and ****, indicate p-values < 0,05, ≤0.005, ≤0.001, and <0.0001, respectively Source data and exact p values are provided in the Source Data file.